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Since its introduction nearly 100 years ago,1 
arthroscopy of the knee has revolutionised the care 
of patients with meniscal lesions, ruptures of the 
anterior cruciate ligament, and cartilage damage. 
Although knee arthroscopy has proved to be an asset 
that is highly beneficial to many patients, it is not a 
panacea for all knee problems. The clinical benefit is 
especially questionable for patients with degenerative 
osteoarthritis: in a trial using a sham surgery,2 knee 
arthroscopy had no effect, and this finding was 
confirmed in another study.3 The difficulty of implanting 
evidence-based surgery in daily surgical practice is 
highlighted by the large number of patients who still 
have arthroscopy in osteoarthritic knees.4
The possibility of arthroscopy in joints other than the 
knee has also been explored. Shoulder arthroscopy has 
been taken up widely,5,6 although indications are not 
clearly defined. Two areas that are possibly indicated are 
the glenohumeral joint for intra-articular lesions and the 
subacromial area that is extra-articular. An impingement 
syndrome of the subacromial area is responsible for up to 
70% of all shoulder problems.7 This impingement arises 
due to the restricted space between the acromion and 
the glenohumeral head, where rotator cuff tendons slice 
back and forth in abduction and ante version, facilitated 
by a subacromial bursa. An impingement of these rotator 
cuff tendons occurs frequently in patients older than 
40 years, with typical complaints such as a painful arc.8 
To overcome this impingement problem, in 1972 Neer8 
proposed open decompression of this area, removing 
osseous spurs from the caudal side of the acromion, 
often combined with release of the coracoacromial 
ligament and a bursectomy. An arthroscopic version 
of this popular procedure was developed and is 
now frequently undertaken, with an increase of 
nearly ten times in England from 2500 surgeries in 
2000 to 21 000 in 2010.6
However, as correctly pointed out in The Lancet by 
David Beard and colleagues9 for the Can Shoulder 
Arthroscopy Work (CSAW) study group, the scientific 
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clinical evidence in favour of this type of shoulder 
surgery is scarce. In Beard and colleagues’ multicentre, 
pragmatic, parallel group, placebo-controlled, three-
group, randomised surgical trial, 106 patients were 
assigned to decompression surgery, 103 to arthroscopy 
only, and 104 to no treatment. The primary outcome 
was the Oxford Shoulder Score at 6 months, analysed by 
intention to treat.9
The study group should be commended for 
undertaking this difficult trial. Two factors that 
made an assessment of effect difficult were 
the rather high level of non-compliance in the 
groups (24 [23%], 43 [42%], and 12 [12%] of the 
decompression, arthroscopy only, and no-treatment 
groups, respectively, did not receive their assigned 
treatment, making the groups more similar and thus 
differences harder to detect) and the long waiting list, 
with a waiting time of up to 4 months considered 
to be acceptable. Thus, patients who were only 
2 months post surgery were compared with patients 
who were 6 months into the no-treatment option. 
However, the outcome was still remarkable. There 
was no difference in the primary outcome between 
the arthroscopic decompression and arthroscopy only 
groups (decompression mean 32·7 points [SD 11·6] vs 
arthroscopy mean 34·2 points [9·2]; mean difference 
–1·3 points [95% CI –3·9 to 1·3], p=0·3141). This is 
an intriguing finding, showing that subacromial 
decompression does not affect the clinical outcome.
Additionally, although patients in the surgical groups 
had statistically better outcomes than the no-treatment 
group, the differences were small and not clinically 
important. Although the sizes of the differences are 
difficult to interpret because of the high non-compliance 
levels and long waiting list, the differences themselves 
might be attributed to the placebo effect after surgery. 
Another explanation, but also a criticism of the study 
design, is that the no-treatment group was left alone 
(one reassessment appointment with a specialist 
shoulder clinician 3 months after study entry but no 
intervention) in this study with no offered rehabilitation 
programme, unlike the surgical groups.
The findings send a strong message that the burden 
of proof now rests on those who wish to defend 
the standpoint that shoulder arthroscopy is more 
effective than non-surgical interventions. Hopefully, 
these findings from a well respected shoulder research 
group will change daily practice. The costs of surgery are 
high, and although the low occurrence of complications 
might suggest that the surgery is benign,10 there is no 
indication for surgery without possible gain. Therefore, 
the focus on the cure for these patients should be 
on developing effective conservative treatment 
programmes based on exercise and probably combined 
with tape, manual therapy, extracorporeal shockwave 
lithotripsy, or laser treatment.11
The emerging pattern that arthroscopic interventions 
might, for some indications, not be more beneficial 
than non-surgical options should also be taken into 
consideration when the decision for hip arthroscopy is 
made. There is a worrisome trend to do arthroscopy of 
the hip, including in elderly patients with degenerative 
hips.12 The orthopaedic field is in urgent need of well 
designed studies that assess the effectiveness of this 
kind of surgery in osteoarthritic hips.13
Arthroscopy is a useful procedure that benefits many 
patients. However, there are serious concerns that 
a substantial number of these procedures are done 
in patients with mostly degenerative diseases, and 
therefore will not be curative. Unfortunately, it will 
be demanding to change daily orthopaedic practice as 
both patients and surgeons believe sincerely that the 
problems will be reduced after arthroscopic surgery. 
Evidence such as that reported by the CSAW study 
group should help to change such views and improve 
practice.
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There is a well documented association between 
human exposure to fine particulate matter air pollution 
(PM2.5) and an increased risk of cardiovascular disease 
and death.1,2 Indeed, the Global Burden of Disease 
(GBD) study3 recently estimated that exposure to PM2·5 
contributed to 4·2 million deaths in 2015, representing 
the fifth-ranked risk factor for global deaths; of these, 
mortality from cardiovascular disease (CVD; ie, ischaemic 
heart disease and cerebrovascular disease) accounted 
for most deaths attributed to ambient PM2·5 air 
pollution. However, despite these strong epidemiological 
associations and the documented widespread adverse 
health effects, the exact biological mechanisms and 
the types of particles that are most responsible for the 
PM2.5–CVD associations are not well defined.
In The Lancet, Rudy Sinharay and colleagues4 use a 
simple but elegant randomised crossover design to gain 
insight into the type of pollution that can lead to the 
air pollution–CVD associations that have been reported 
in population-based epidemiological studies, as well as 
to identify specific cardiovascular changes consistent 
with the causality of those associations. The researchers 
studied the effects of traffic pollution exposure in adult 
participants aged 60 years and older during a 2 h walk 
along a busy commercial street in London, England 
(Oxford Street) compared with a similar walk in a 
nearby London park (Hyde Park), which has much lower 
air pollution. 40 healthy volunteers, 40 participants 
with chronic obstructive pulmonary disease, and 
39 participants with ischaemic heart disease took part. 
In all 119 participants, irrespective of disease status, 
walking in Hyde Park led to an increase in lung function 
and a decrease in arterial stiffness, measured as pulse 
wave velocity and augmentation index, following 
the walk. By contrast, these beneficial responses were 
significantly diminished after walking along the more 
polluted Oxford Street. Specifically, among healthy 
volunteers the investigators reported a roughly 5% 
(95% CI –10·40 to –0·27) decrease in pulse wave velocity 
from 2 to 26 h after the Hyde Park walk, an exercise 
benefit that was not only negated but even reversed 26 h 
after the Oxford Street walk (7% increase in pulse wave 
velocity, 95% CI 2·16 to 12·20). Thus, the multifactorial 
benefits of low-to-moderate intensity physical 
activity, such as walking, for the primary and secondary 
prevention of CVD5 were offset by the presence of air 
pollution. Reductions in measures of arterial stiffness 
have been recorded with the use of guideline-directed 
medical therapy;6 however, until this study, evidence 
has been scarce on the adverse effects of air pollution 
exposure on vascular function during physical activity.7
Important to the interpretation of this study is 
the finding that air pollution causes phospholipid 
oxidation8 and oxidative stress (eg, by transition metals 
in fossil fuel combustion particles).9 These pathways 
accelerate atherogenesis and increase arterial stiffness, 
itself a strong predictor of cardiovascular events and all-
cause mortality.10 However, one limitation of such panel 
studies is their size; as such, generalisability can be an 
issue. In view of this limitation, more and larger practical 
real-world exposure studies like the one done by Sinharay 
and colleagues4 that also assess novel in-vivo biomarkers 
of oxidative stress and phospholipid oxidation might 
further clarify the mechanistic pathways and clinical 
implications of air pollution exposure, and broaden their 
known applicability. Furthermore, additional evidence on 
the temporal relationships and longer-term cumulative 
effects of chronic air pollution on arterial stiffness is 
also needed. Overall, however, data from Sinharay 
and colleagues provide significant new evidence of an 
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